For adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are stable on intravenous immunoglobulin (IVIg), how does switching to subcutaneous immunoglobulin (SCIg) maintenance treatment compare with placebo?
Cochrane Clinical Answers · 09.11.2026
DOI: 10.1002/cca.4884 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cochrane Clinical Answers, online erschienen am 09.11.2026. Verfasst von Agustín Ciapponi. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Ciapponi, A. (2026). For adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are stable on intravenous immunoglobulin (IVIg), how does switching to subcutaneous immunoglobulin (SCIg) maintenance treatment compare with placebo?. Cochrane Clinical Answers. https://doi.org/10.1002/cca.4884
Vancouver
Ciapponi A. For adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are stable on intravenous immunoglobulin (IVIg), how does switching to subcutaneous immunoglobulin (SCIg) maintenance treatment compare with placebo?. Cochrane Clinical Answers. 2026. doi:10.1002/cca.4884
BibTeX
@article{Ciapponi2026,
author = {Ciapponi, Agustín},
title = {For adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are stable on intravenous immunoglobulin (IVIg), how does switching to subcutaneous immunoglobulin (SCIg) maintenance treatment compare with placebo?},
journal = {Cochrane Clinical Answers},
year = {2026},
doi = {10.1002/cca.4884}
}
EUVIMED